Selena Simmons-Duffin

The House of Representatives is expected to approve a bill Thursday that aims to lower prescription drug prices. Some elements have Republican support. But the bill faces an uncertain Senate future.

Speaker Pelosi’s landmark prescription drug legislation is slated to get a vote in the House Thursday. It’s a sweeping bill on an issue voters care about, but it’s unlikely to become law.

Democratic presidential candidates are debating Medicare For All, but that term isn’t a good descriptor of the plans being put forth. Clarifying this health care vocabulary helps the debate.

The White House announced Tuesday it will begin distribution of free HIV-prevention medication to people without prescription drug coverage. It’s part of Trump’s plan to end HIV in the U.S. by 2030.

The summer kicked off with a blitz of government activity to end surprise medical billing, but lobbying, impeachment, and policy arguments have left the future of the legislation up in the air.

Five U.S. territories say if Congress doesn’t quickly allocate more funding for their Medicaid programs, they will be forced to make brutal triage decisions that will likely cost American lives.

This year the federal health insurance marketplace Healthcare.gov has a few new bells and whistles. (This piece initially aired on Nov. 3, 2019 on Weekend Edition Sunday.)

Two regulations announced Friday take aim at health care prices. One, to affect patients by 2021, addresses hospital rates. The second, a proposal, would require more upfront clarity from insurers.

The federal government is suing drugmaker Gilead for alleged patent infringement. The suit charges the company violated patents on “PrEP” drugs that are used to prevent HIV infection.

A federal judge has thrown out the Trump administration’s “conscience rights” rule for health care workers.